Soaring U.K. energy costs top drug manufacturers concerns; Canada cuts OTC red tape;

 @EricPFierce: Genzyme says the FDA and EMA have signed off a second fill-finish operation for a couple of drugs at the upgraded plant in Ireland. Report | Follow @EricPFierce

> Soaring energy costs in the U.K. top the list of concerns for drug and chemical manufacturers there, according to a survey by a trade association. Story

> The U.K.'s Medicines and Healthcare products Regulatory Agency says it has a new plan for protecting consumers and fighting counterfeit drugs from getting into the authorized supply chain. News

> Almac has installed a blister line at its new plant in Audobon, PA. that is capable of producing 12,000 blister packs an hour in a series of sizes. Item

> Canada is eliminating a regulatory process, which will cut about a year out of the time it takes to move a branded drug to over-the-counter designation after its been given approval. More

> AMRI is expanding its contract manufacturing and outsourcing efforts. Article

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.